Original Articles
Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion
Michael H. Barnett MBBS,
John W. Prineas MBBS,
Michael H. Barnett MBBS
Institute of Clinical Neurosciences, Department of Medicine, University of Sydney, Australia
Search for more papers by this authorCorresponding Author
John W. Prineas MBBS
Institute of Clinical Neurosciences, Department of Medicine, University of Sydney, Australia
Department of Medicine, Blackburn Building D06, University of Sydney, NSW 2006 AustraliaSearch for more papers by this author
Michael H. Barnett MBBS,
John W. Prineas MBBS,
Michael H. Barnett MBBS
Institute of Clinical Neurosciences, Department of Medicine, University of Sydney, Australia
Search for more papers by this authorCorresponding Author
John W. Prineas MBBS
Institute of Clinical Neurosciences, Department of Medicine, University of Sydney, Australia
Department of Medicine, Blackburn Building D06, University of Sydney, NSW 2006 AustraliaSearch for more papers by this authorAbstract
The study describes the clinical and pathological findings in 12 patients with relapsing and remitting multiple sclerosis, who died during or shortly after the onset of a relapse. Pathological changes not previously associated with the formation of new symptomatic lesions were observed in seven cases, namely, extensive oligodendrocyte apoptosis and microglial activation in myelinated tissue containing few or no lymphocytes or myelin phagocytes. No current laboratory model of multiple sclerosis, in particular, experimental allergic encephalomyelitis, is known with these features, which raises the possibility of some novel process underlying new lesion formation in multiple sclerosis. Ann Neurol 2004;55:000–000
Supporting Information
Supplementary material to this article can be viewed online at www.interscience.wiley.com/suppmat/0364-5134/suppmat/index.html
| Filename | Description |
|---|---|
| suppmat_page.pdf1.2 MB | Supporting Information file suppmat_page.pdf |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Adams CW, Poston RN, Buk SJ. Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis. J Neurol Sci 1989; 92: 291–306.
- 2 Naoumenko J, Feigin I. A stable silver solution for axon staining in paraffin sections. J Neuropathol Exp Neurol 1967; 26: 669–673.
- 3 Van Noorden S. Principles of immunostaining. In: MI Filipe, BD Lake, eds. Histochemistry in pathology. 2nd ed. Edinburgh: Churchill Livingstone, 1990: 31–47.
- 4 McGeer PL, Kawamata T, Walker DG, et al. Microglia in degenerative neurological disease. Glia 1993; 7: 84–92.
- 5 Nakopoulou L, Alexandrou P, Stefanaki K, et al. Immunohistochemical expression of caspase-3 as an adverse indicator of the clinical outcome in human breast cancer. Pathobiology 2001; 69: 266–273.
- 6 Boor JW, Johnson RJ, Canales L, et al. Reversible paralysis of automatic respiration in multiple sclerosis. Arch Neurol 1977; 34: 686–689.
- 7 Crawley F, Saddeh I, Barker S, et al. Acute pulmonary oedema: presenting symptom of multiple sclerosis. Mult Scler 2001; 7: 71–72.
- 8 Giroud M, Guard O, Dumas R. [Cardio-respiratory anomalies in disseminated sclerosis]. Rev Neurol (Paris) 1988; 144: 284–288.
- 9 Simon RP, Gean-Marton AD, Sander JE. Medullary lesion inducing pulmonary edema: a magnetic resonance imaging study. Ann Neurol 1991; 30: 727–730.
- 10 Maeda Y, Solanky M, Menonna J, et al. Platelet-derived growth factor-alpha receptor-positive oligodendroglia are frequent in multiple sclerosis lesions. Ann Neurol 2001; 49: 776–785.
- 11 Di Bello IC, Dawson MR, Levine JM, et al. Generation of oligodendroglial progenitors in acute inflammatory demyelinating lesions of the rat brain stem is associated with demyelination rather than inflammation. J Neurocytol 1999; 28: 365–381.
- 12 Moore GR, Berry K, Oger JJ, et al. Balo's concentric sclerosis: surviving normal myelin in a patient with a relapsing-remitting clinical course. Mult Scler 2001; 7: 375–382.
- 13 Cotton F, Weiner HL, Jolesz FA, et al. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003; 60: 640–646.
- 14 Silver NC, Lai M, Symms MR, et al. Serial magnetization transfer imaging to characterize the early evolution of new MS lesions. Neurology 1998; 51: 758–764.
- 15 Youl BD, Turano G, Miller DH, et al. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991; 114: 2437–2450.
- 16 Brück W, Schmied M, Suchanek G, et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994; 35: 65–73.
- 17 Dowling P, Husar W, Menonna J, et al. Cell death and birth in multiple sclerosis brain. J Neurol Sci 1997; 149: 1–11.
- 18 Lucchinetti CF, Brück W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996; 6: 259–274.
- 19 Storch MK, Piddlesden S, Haltia M, et al. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998; 43: 465–471.
- 20 Yao DL, Webster HD, Hudson LD, et al. Concentric sclerosis (Balo): morphometric and in situ hybridization study of lesions in six patients. Ann Neurol 1994; 35: 18–30.
- 21 Prineas JW. The neuropathology of multiple sclerosis. In: PJ Vinken, GW Bruyn, GW Klawans, et al., eds. Handbook of clinical neurology. Vol 47. Amsterdam: Elsevier, 1985: 213–257.
- 22 Aboul-Enein F, Rauschka H, Kornek B, et al. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 2003; 62: 25–33.
- 23 Gay FW, Drye TJ, Dick GW, et al. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997; 120: 1461–1483.
- 24 Itoyama Y, Sternberger NH, Webster HD, et al. Immunocytochemical observations on the distribution of myelin-associated glycoprotein and myelin basic protein in multiple sclerosis lesions. Ann Neurol 1980; 7: 167–177.
- 25 Lassmann H. Classification of demyelinating diseases at the interface between etiology and pathogenesis. Curr Opin Neurol 2001; 14: 253–258.
- 26 Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707–717.
- 27 Rodriguez M, Scheithauer BW, Forbes G, et al. Oligodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin Proc 1993; 68: 627–636.
- 28 Graeber MB, Blakemore WF, Kreutzberg GW. Cellular pathology of the central nervous system. In: DI Graham, PL Lantos, eds. Greenfield's neuropathology. 7th ed. London: Arnold, 2002: 148–150.
- 29 Kirk J. The fine structure of the CNS in multiple sclerosis. II. Vesicular demyelination in an acute case. Neuropathol Appl Neurobiol 1979; 5: 289–294.
- 30 Raine CS, Cannella B, Hauser SL, et al. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol 1999; 46: 144–160.
- 31 Brück W, Porada P, Poser S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995; 38: 788–796.
- 32 Solanky M, Maeda Y, Ming X, et al. Proliferating oligodendrocytes are present in both active and chronic inactive multiple sclerosis plaques. J Neurosci Res 2001; 65: 308–317.
- 33 Carroll WM, Jennings AR. In vivo CNS remyelination: HNK-1 labels newly differentiated oligodendrocytes but not precursors. J Neurocytol 1993; 22: 583–589.
- 34 Chari DM, Blakemore WF. New insights into remyelination failure in multiple sclerosis: implications for glial cell transplantation. Mult Scler 2002; 8: 271–277.
- 35 Dawson MR, Levine JM, Reynolds R. NG2-expressing cells in the central nervous system: are they oligodendroglial progenitors? J Neurosci Res 2000; 61: 471–479.
- 36 Bartnik BL, Juurlink BH, Devon RM. Macrophages: their myelinotrophic or neurotoxic actions depend upon tissue oxidative stress. Mult Scler 2000; 6: 37–42.
- 37 Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci 2002; 3: 705–714.
- 38 Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–285.
- 39 Prineas JW, Raine CS. Electron microscopy and immunoperoxidase studies of early multiple sclerosis lesions. Neurology 1976; 26: 29–32.
- 40 Prineas JW, Connell F. The fine structure of chronically active multiple sclerosis plaques. Neurology 1978; 28: 68–75.
- 41 Nyland H, Matre R, Mork S. Fc receptors of microglial lipophages in multiple sclerosis. N Engl J Med 1980; 302: 120–121.
- 42 Adams CW, Poston RN. Macrophage histology in paraffin-embedded multiple sclerosis plaques is demonstrated by the monoclonal pan-macrophage marker HAM-56: correlation with chronicity of the lesion. Acta Neuropathol (Berl) 1990; 80: 208–211.
- 43 Petrescu A. Histochemistry of lipids in multiple sclerosis. Wien Z Nervenheilkd Grenzgeb 1969; 2(suppl 2): 38–52.
- 44 Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001; 2: 589–598.
- 45 Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000; 407: 784–788.
- 46 McGeer PL, Kawamata T, Walker DG, et al. Microglia in degenerative neurological disease. Glia 1993; 7: 84–92.
- 47 Henson PM, Bratton DL, Fadok VA. The phosphatidylserine receptor: a crucial molecular switch? Nat Rev Mol Cell Biol 2001; 2: 627–633.
- 48 Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998; 101: 890–898.
- 49 De Simone R, Ajmone-Cat MA, Tirassa P, et al. Apoptotic PC12 cells exposing phosphatidylserine promote the production of anti-inflammatory and neuroprotective molecules by microglial cells. J Neuropathol Exp Neurol 2003; 62: 208–216.
- 50 Casaccia-Bonnefil P. Cell death in the oligodendrocyte lineage: a molecular perspective of life/death decisions in development and disease. Glia 2000; 29: 124–135.
10.1002/(SICI)1098-1136(20000115)29:2<124::AID-GLIA5>3.0.CO;2-O CASPubMedWeb of Science®Google Scholar
- 51 Magnus T, Chan A, Savill J, et al. Phagocytotic removal of apoptotic, inflammatory lymphocytes in the central nervous system by microglia and its functional implications. J Neuroimmunol 2002; 130: 1–9.
- 52 Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115–121.
- 53 Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci 2003; 206: 187–191.
- 54 Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55: 300–309.
- 55 Selmaj K, Raine CS, Farooq M, et al. Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J Immunol 1991; 147: 1522–1529.
- 56 Hofman FM, Hinton DR, Johnson K, et al. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170: 607–612.
- 57 Merrill JE, Ignarro LJ, Sherman MP, et al. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 1993; 151: 2132–2141.
- 58 Bo L, Dawson TM, Wesselingh S, et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994; 36: 778–786.
- 59 Bonetti B, Raine CS. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 1997; 42: 74–84.
- 60 Dowling P, Shang G, Raval S, et al. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 1996; 184: 1513–1518.
- 61 Trapp BD, Bo L, Mork S, et al. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 1999; 98: 49–56.
- 62 Raine CS. The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 1994; 36(suppl): S61–S72.
- 63 Barnett M, Prosser J, Sutton I, et al. Paraneoplastic brain stem encephalitis in a woman with anti-Ma2 antibody. J Neurol Neurosurg Psychiatry 2001; 70: 222–225.
- 64 Mendez MF, Pogacar S. Malignant monophasic multiple sclerosis or “Marburg's disease.” Neurology 1988; 38: 1153–1155.
- 65 Prineas JW, Barnard RO, Kwon EE, et al. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993; 33: 137–151.
